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ABSTRACT
Objective: Interleukin-10 (IL-10) is an anti-inflammatory
cytokine that suppresses lymphocyte functions, regulates
production of proinflammatory cytokines, and suppress-
es nitric oxide production by activated macrophages. We
examined IL-10 expression and its value as a surrogate
index for nitric oxide (NO) production in endothelial cul-
tures obtained from saphenous vein samples. 
Methods: Using 2 different techniques (the open and
endoscopic), we harvested samples of human saphenous
veins from 90 randomly selected patients undergoing
coronary artery bypass surgery (CABG). Endothelial cells
collected from the vein samples retrieved through both
techniques were cultured for 72 hours. Using a solid
phase enzyme linked-immuno-sorbent assay (ELISA), we
analyzed pre- and postoperative sera, in addition to the
supernatants from the cultures, for IL-10. 
Results: Mean preoperative levels of IL-10 (0.09 ± 0.04
pg/mL) did not differ significantly from that for postop-
erative sera (0.14 ± 0.17 pg/mL) (P = 0.54). Mean IL-10
levels for endothelial cell culture supernatants did not
differ significantly between the endoscopic (0.32 ± 0.39
pg/mL) and the open method (0.46 ± 0.80 pg/mL) (P =
0.30). 
Conclusion: Our findings indicate that endoscopic and
open saphenectomies are technically comparable with
respect to their effects on IL-10 release during saphenous
vein harvesting for CABG. We recommend the endo-
scopic method for its low morbidity and earlier hospital
discharge. 
Key Words: Interleukin-10, Endoscopic saphenous vein
harvesting, Coronary artery bypass grafting.
INTRODUCTION
Cytokines play an important role in the recruitment of
leukocytes from blood to sites of tissue injury and inflam-
mation.1-6 IL-10, a pleotropic mediator, inhibits the pro-
duction of cytokines by macrophages and downregulates
their antigen-presenting function. By identification of the
cytokine networks and their mechanism of action, we
have a better understanding of the regulatory role of IL-10
and other cytokines on endothelial cells leading to inflam-
matory and allergic reactions.7
IL-10 was originally characterized as a cytokine that
inhibits certain immune responses and was described as a
“cytokine synthesis inhibitory factor.”8 It was recently dis-
covered that IL-10 has the ability to inhibit synthesis of
other cytokines, T-cell proliferation, and nitric oxide (NO)
formation suggesting its immunosuppressive potential.9,10
IL-10 is synthesized by T helper-2 cells, CD-8 cells, mono-
cytes,11 keratinocytes,12 activated B cells and lympho-
cytes.13 IL-10 also has a direct stimulatory effect on B-cells
and promotes antibody production. IL-10 downregulates
endothelial cell adhesion molecules resulting in decreased
leukocyte adhesion, a process that is probably mediated
through NO release. NO seems to be an important medi-
ator of many biological functions including vascular dilata-
tion, microbicidal activity, and platelet aggregation. IL-10
has important and highly significant inhibitory activities on
immune and vascular functions. These actions seem to be
derived in part from its ability to diminish various immune
and endothelial functions by suppression of cellular activ-
ity. IL-10 levels measured at 6 hours after cardiopulmonary
bypass surgery are higher than levels found during sur-
gery. This postsurgical increase in IL-10 levels may be an
immunoregulatory attempt to downregulate the diffuse
inflammation associated with the trauma of surgery.14,15
The purpose of this study was to examine the expression
of IL-10 and its value as a surrogate index for the produc-
tion of NO in endothelial cultures that are obtained from
saphenous vein samples. These samples were obtained by
2 methods of vein harvesting performed during coronary
artery bypass grafting (CABG), a new endoscopic saphe-
nous vein harvesting method (ESVH), and a conventional
open vein harvesting method (OSVH).
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METHODS
Vein Retrieval 
The study was conducted at Maimonides Medical Center
(MMC) from November 1998 to May 1999. Saphenous
veins were harvested from 45 patients prepared for CABG.
In the standard technique of open (no-touch) vein har-
vesting, the greater saphenous vein is exposed and har-
vested under direct vision through a long, continuous skin
incision with the patient’s leg in a “frog-leg” position.
Whereas in the endoscopic technique, a small incision is
made 4-finger breadths posterior to the proximal margin of
the patella, the greater saphenous vein is identified, dis-
sected both cranially and distally under endoscopic visual-
ization through the incision and then stripped and
retrieved. The standard instrumentation used in the proce-
dure is commercially known as the Endo-Path (Ethicon
Endo-Surgery, Inc, Cincinnati, OH). It comprises a subcu-
taneous dissector, retractor, and a modified vein stripper.
In addition, standard endoscopic equipment including a
television monitor, light source, fiber-optic camera, and a
5-mm lens were used.
We sampled 2 vein segments, each by using 1 of the 2 har-
vesting techniques, from the same leg of each study
patient. This was done by excising a 5-cm segment of the
thigh portion of the saphenous vein cranially dissected and
retrieved endoscopically as the endoscopic sample. The
sample was clipped distally for orientation of blood flow
direction. At the same time, the vein segment remaining at
the site of the incision about 10 cm in length was excised
as the direct or open sample. 
The veins were harvested and handled under sterile con-
ditions according to the operating room protocol at MMC.
Vein Preparation 
Vein samples were incubated in 10 mL Dulbecco’s
Modified Eagle Medium (1X), liquid high glucose (D-MEM)
with 200 mL penicillin-streptomycin during transport to the
laboratory. In the laboratory, each vein sample was flushed
and cannulated, injected with plasmalyte, and the branch-
es were ligated with 3.0 silk sutures. 
Endothelial Cell Culture 
At the conclusion of the previous procedure, vein samples
were collected and transported using the same transport
medium (D-MEM). Then, under a laminar flow hood, the
pair of veins (OSVH and ESVH) was put into a Petri dish
containing 5 mL of endothelial cell culture medium [IMDM
with 25 mM HEPES, 3.024 g/L NaHCO3, 100 U/mL peni-
cillin, 100 µ/mL streptomycin, 15% FBS (fetal bovine
serum), 30 µ/mL ECGS, 130 µ/mL heparin, and 2 mM L-
glutamine]. 
Each vein was flushed with the indicated solution and
divided into 2 pieces with a sterile scalpel (No. 15 blade).
The proximal piece was used for culture (see below), and
the distal one for microscopic analysis (light and electron
microscopy, both scanning and transmission). The proxi-
mal piece of the vein was slit open so that it lay flat. The
luminal surface was scraped with a sterile scalpel (No. 11
blade) using light, single strokes, covering each area only
once. Cells that built up on the scalpel blade were shaken
off into the endothelial culture medium. The vein there-
after was rinsed in the culture medium, and the super-
natant-containing endothelial cells were then preserved in
25 mL culture flasks. These flasks were then incubated at
37°C and 5% CO2 with humidifier for the next 72 hours.
IL-10 Measurements
The Bio-Source Cytoscreen™ human IL-10 (h IL-10), a
solid phase sandwich enzyme linked-immuno-sorbent
assay (ELISA) was used for quantitative determination of
human IL-10 (hIL-10). This is a sensitive ELISA with an
antibody specific for hIL-10 coated on to the wells of the
micro-titer strips. 
Statistics
Data are presented as mean ± standard deviation. The 2-
tailed Student t test was used to compare the mean ex-
pression values of hIL-10 with a level of significance at P
= 0.05 or less.
RESULTS
The mean concentration of IL-10 in preoperative sera was
0.09 pg/mL ± 0.04, and that in postoperative sera was 0.14
pg/mL ± 0.17, the difference not being statistically signifi-
cant (P = 0.54). Similarly, no significant difference (P =
0.30) existed in the mean concentration of IL-10 in
endothelial cell culture supernatants obtained by OSVH
(0.46 pg/mL ± 0.80) and the ESVH (0.32 pg/mL ± 0.39)
(Table 1).DISCUSSION
Coronary artery bypass grafting (CABG) initiates a cascade
of events that results in systemic cytokine release.16
Cytokine release depends on the strength of trauma inflict-
ed on vascular endothelial cells. Numerous reports have
documented the presence and changes in cytokine levels
during surgical trauma. 
Vascular endothelial cells constitute the interface between
the blood stream and the tissues. Endothelial cells might
perform several key roles in the development of inflam-
matory responses including adhesion to inflammatory
leukocytes and control of vascular permeability.17-21
However, the vascular endothelium is unlikely to be
exposed to the local action of a single cytokine in vivo.
The concerted action of a range of leukocyte-derived sig-
nals, acting sequentially or in concert, is responsible for
the eventual outcome of potentially inflammatory events.22 
IL-10 was initially described as an inhibitor of cytokine
production and antigenic-specific proliferation of CD4+ T
helper cells in mice.23 IL-10 is a cytokine produced by acti-
vated macrophages and some lymphocytes. IL-10 is now
known to have multiple biological activities. Many studies
have demonstrated that IL-10 inhibits macrophage synthe-
sis of the inflammatory cytokine IL-1 and tumor necrosis
factor-α (TNF-α). On the other hand, IL-10 is produced as
a result of IL-1 and TNF-α stimulation from the very cell
that secretes the proinflammatory cytokine in an attempt
to downregulate their excitatory actions.24-26 It was
demonstrated that IL-10 stimulates the release of NO from
human saphenous vein endothelium. The NO release can
be antagonized by an antibody to IL-10 and by nitric oxide
synthases (NOS). Removal of the endothelium also results
in a lack of response to IL-10 suggesting that IL-10 exerts
its action through endothelial NO. Furthermore, IL-10-cou-
pled NO release is of functional significance in that the
adherence of human granulocytes and monocytes to vein
endothelium can be diminished after IL-10 exposure.
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Presumably, this occurs because of the presence and
action of NO on the immunocytes or endothelium or both. 
Recently, a newly developed technique of saphenous vein
harvesting, endoscopic harvesting, has been described
and practiced in the United States. It was well understood
that steps involved in the preparation and handling of the
saphenous vein were critically important and had a major
impact on the eventual health and patency of the con-
structed bypass conduit. In our present study, we demon-
strated that no significant difference exists in the level of
IL-10 in pre- and postoperative sera in either the OSVH or
ESVH technique. 
Our study demonstrates that no significant difference
exists in the average pre- and postoperative levels of IL-
10. In addition, neither saphenous vein harvesting (OSVH
or ESVH) technique changed average IL-10 levels. The
comparability between the 2 methods suggests that vein
manipulation and minor physical shears in operative
extraction of the vein conduit would have minimal impact
on IL-10 and therefore NO release from endothelial cells,
which will subsequently affect the performance of the
vein conduit. 
One limitation of this study is that we evaluated the levels
of IL-10 in the supernatants of the endothelial cell cultures
for 72 hours only. Follow-up that requires culture for a
longer period, and additionally, daily measurement of the
cytokine would be more accurate than single measure-
ments. 
The other disturbing limitation was the effect of car-
diopulmonary bypass that causes activation of leukocytes,
especially neutrophils, with the release of a number of
cytokines, such as IL-1, IL-2, TNF-α, and INF-γ. These
cytokines and other released factors in the blood can
cause upregulation of adhesion molecules and thus affect
future performance of bypass conduits. The pathway and
the complexity of up- and downregulation of various
adhesion molecules and cytokines including endothelial
cell culture and viability have been reported previously,
showing comparable results for both techniques.26-27 
The light and the electron microscopic study of both har-
vesting techniques showed comparable results comparing
variable parameters of vein injury.28 
Longer follow-up of the patency rate of saphenous vein
grafts in patients who had CABG with the endoscopic
technique for vein harvesting and comparing them to ran-
Table 1.
Mean IL-10 concentrations (pg/mL) pre- and post-CABG, and in
endothelial cell culture supernatants from saphenous veins har-
vested with the endoscopic or open techniques.
Preoperative Postoperative Endoscopic Open
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domly selected patients with grafts harvested by the tradi-
tional technique will be required to further validate our
results.
CONCLUSION
The comparable results of IL-10 release in both harvesting
techniques of the saphenous vein indicate that the novel
endoscopic technique is equivalent to the open technique.
This endoscopic technique is safe and unique for vein
preparation during CABG surgery, keeping in mind its low
morbidity rates. Thus, this method is a reasonable alterna-
tive to the standard open method and has several poten-
tial advantages.
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